|
KMID : 0370220210650060494
|
|
Yakhak Hoeji
2021 Volume.65 No. 6 p.494 ~ p.501
|
|
|
The R&D Scale and Status of Global Pharmaceutical Companies in Korea: Survey for 5 years from 2016 to 2020
|
|
Oh In-Sun
Cho Hye-Won
Lee Hyun-Joo
Song Hye-Won
Han Na-Rae
Kim Cho-Rong
Lim Hye-In
Shin Ju-Young
|
|
|
Abstract
|
|
|
While the importance of the global pharmaceutical industry is growing owing to continued new drugdevelopments and R&D investments, the scale of global pharmaceutical companies in Korea remains unclear. We thereforeinvestigated the R&D status of global pharmaceutical companies in Korea through an annual survey from 2016 to 2020.
We assessed five factors annually and their trend over the 5-year period: costs, personnel, number of clinical trials, numberof clinical trial subjects, and others. We then examined the correlation among factors and further compared the trendbetween each factor and the gross domestic product (GDP). Of 35 companies that responded, 25 responded for fiveconsecutive years and showed a steady increase in the cost, personnel, and the number of clinical trials. While costs andpersonnel increased more than the GDP over the 5-year period, the number of clinical trials remained similar; number ofclinical trial subjects highly fluctuated year-by-year. Moreover, a high correlation was found for cost and personnel(r>0.8852), and cost and the number of clinical trials (r>0.8452). In conclusion, costs, personnel, and the number ofclinical trials of global pharmaceutical companies in Korea steadily increased from 2016 to 2020 and thus, havecontinuously contributed to the domestic economy.
|
|
|
KEYWORD
|
|
|
Global pharmaceutical companies, Survey, Research and development,, Cost
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|